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Borderline ovarian tumours are epithelial ovarian cancers of low
malignant potential, characterized by limited invasiveness,
favourable prognosis and relatively early age at onset (Hart, 1977;
Scully, 1982). Most information comes from clinical series
(Barnhill et al, 1985; Nakashima et al, 1990; Rice et al, 1990;
Leake et al, 1992; Kærn et al, 1993; Kennedy and Hart, 1996).
Among the few published epidemiological series, the Western
Washington Cancer Surveillance System (Harlow et al, 1987)
showed a rising incidence between 1975 and 1983, from 0.7 to 3.9
per 100 000, a more modest rise with age compared with invasive
neoplasms, and a 93% 5-year survival; 90 out of 168 (54%) cases
were serous and 78 (46%) mucinous. In a clinical series of 370
patients (median age 53 years) treated between 1970 and 1982 at
the Norwegian Radium Hospital (Kærn et al, 1993), 5-year
survival was over 90% for both mucinous (48% of cases) and
serous (47%) neoplasms. A total of 1197 borderline ovarian
tumours were reported to the Finnish Cancer Registry between
1973 and 1992 (Auranen et al, 1996), corresponding to an age-
standardized incidence of 1.8 per 100 000. Mean age was 52 years,
and the incidence did not increase over age 35. Data from the
Cancer Registry of Norway over the period 1954–93 showed an
upward trend in incidence, reaching an age-adjusted rate of 4.8 per
100 000 in 1989–93. The incidence rose up to age 55, and then
levelled off, and over 90% of neoplasms were localized (Bjorge et
al, 1997). In Israel, the age-adjusted rate approached 2 per 100 000
in the early 1990s among Jews, representing about 10% of all
ovarian neoplasms (Iscovich et al, 1998).
To provide further information on the issue, we examined
incidence, survival and the occurrence of second neoplasms in
borderline ovarian cancers diagnosed in the Cancer Registry of the
Swiss Canton of Vaud.
MATERIALS AND METHODS
The data for the present report were abstracted from the Cancer
Registry of the Canton of Vaud (Levi et al, 1997) whose popula-
tion, according to the 1990 census, was about 600 000 inhabitants.
The registry is tumour based, and multiple primaries occurring in
the same patient are entered separately. The basic information
available from the register comprises sociodemographic character-
istics of the patient (i.e. age, sex), primary site and histological
type of the tumour according to the standard International
Classification of Diseases for Oncology (ICD-O; World Health
Organization, 1976), and time of diagnostic confirmation. Passive
and active follow-up are recorded.
Since 1976, a registration scheme, applying the same 
standardized rule as for incident malignancies, has been imple-
mented for borderline ovarian tumours (Levi et al, 1993). Bilateral
ovarian tumours (either synchronous or metachronous) are not
registered separately, unless histologically different. Between 1976
and 1996, 176 histologically verified ovarian tumours labelled as of
borderline malignancy or carcinomas of low malignant potential,
according to the WHO International Classification of Tumours
(Serov et al, 1973) and standard histological criteria and sampling
technical requirements (Czernobilsky, 1987), were registered.
The vital status of each patient included in the present analysis
has been actively verified up to 31 December 1996. On the basis of
these data, survival rates were computed according to the product-
limit (maximum likelihood) method. Relative survival was
derived after allowance for the general life table of the canton. The
persons included in the present series were also followed up to the
end of 1996 for the occurrence of a second primary neoplasm, for
a total of 1444 women–years at risk. Calculation of expected
numbers of cases were based on site-, age- and calendar period-
specific incidence rates, multiplied by the corresponding number
of women–years at risk.
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RESULTS
A total of 176 borderline ovarian tumours were registered, corre-
sponding to an age-adjusted overall incidence (world standard) of
2.7 per 100 000 in the 21-year calendar period considered. These
represented 19% (176 out of 948) of all ovarian neoplasms.
Incidence rose from 1.7 per 100 000 in 1976–81 to 2.7 in 1987–91,
and then levelled off. Incidence rates tended to decline below age
55 (average change per year –8% at age 15–34 and –1.3% at age
35–54, although none of these estimates were significant), but
increased in the elderly. One hundred and two (58%) cases were
serous, 72 (41%) mucinous, and two (1%) other or unspecified.
The age-specific incidence was 2.0 per 100 000 at age 15–34, rose
to 4.1 per 100 000 at age 35–54, and to 4.3 and 4.7 at age 55–74
and ³75 (Table 1).
Overall relative survival was 96% at 5 years, and 94% at 10
years. Ten-year survival was 96% in serous compared with 91% in
mucinous neoplams (Figure 1).
A total of 18 second neoplasms were observed, compared with
10.3 expected. Of these, five (three of ovary and one of right colon
and unknown origin respectively) were synchronous. There was a
significant excess of invasive ovarian cancers (four observed,
including three synchronous primaries, compared with 0.36
expected), but not of any other cancer site.
DISCUSSION
The incidence rates of borderline ovarian tumours from this Swiss
population are lower than those of the US or of Norway but higher
than those of Finland or Israel, presumably in parallel with the
difference in ovarian cancer incidence and mortality rates registered
in these countries (Levi et al, 1994, 1998). This indirectly confirms
that the determinants of invasive and borderline ovarian cancer are
similar, at the population level (Parazzini et al, 1991 a,b).
The present series also confirms the clinical and epidemiolog-
ical observation that the age curve for borderline ovarian tumours,
after rising at younger age, peaks in the fourth and fifth decades, 
to level off thereafter, and that the prognosis of the disease is
favourable, with 94% 10-year survival. This compares well with
the 93% survival from US (Harlow et al, 1987) and the over 90%
10-year survival from Norway (Bjorge et al, 1998).
Of specific interest is the pattern of second neoplasms, showing
a significant excess of invasive ovarian cancers in women with
borderline neoplasms. This is partly attributable to increased diag-
nostic ascertainment, but may further suggest the existence of a
common aetiological pathway between borderline and invasive
ovarian cancer (Parazzini et al, 1991a,b; Leake et al, 1992).
The rises observed in incidence of borderline ovarian tumours
up to the early 1990s, however, are not paralleled by invasive
ovarian cancer trends in this population (Levi et al, 1996). This
suggests that increased diagnostic attention and changes in the
classification may at least in part explain observed rises, although
new risk factors, such as treatments for fertility, have been associ-
ated with the risk of borderline ovarian cancers (Rossing et al,
1994; Parazzini et al, 1998). Incidence rates of borderline ovarian
cancer, however, have been declining in women below age 55, and
more notably below age 35, during the last decade, possibly
reflecting a favourable impact of combined oral contraceptives not
only on invasive (La Vecchia et al, 1996, 1998) but also on border-
line ovarian tumours.
ACKNOWLEDGEMENTS
The contribution of the Vaud Cancer Registry’s staff, and the
collaboration of the pathological laboratories operating in the
Canton of Vaud, are gratefully acknowledged.
Table 1 Trends in age-standardizeda incidence rates per 100 000 women for borderline ovarian tumours from the
Vaud population, Switzerland, according to age group and calendar period, 1976–96
Incidence rate per 100 000 at age
Calendar period
15–34 35–54 55–74 ³75 All ages
Rate (n) Rate (n) Rate (n) Rate (n) Rate (n)
1976–81 0.51 (3) 4.91 (20) 2.93 (10) 2.43 (3) 1.72 (36)
1982–86 3.02 (13) 1.71 (6) 3.25 (9) 2.56 (3) 1.80 (31)
1987–91 2.61 (12) 4.74 (19) 5.14 (14) 7.28 (9) 2.71 (54)
1992–96 2.25 (10) 4.62 (20) 5.99 (16) 6.26 (9) 2.66 (55)
1976–96 2.03 (38) 4.09 (65) 4.29 (49) 4.74 (24) 2.22 (176)
Average change per
year (%) –8.5 –1.3 +4.9b +7.3 +3.2
aAge-standardized rates on the world population. bP < 0.05.






























Figure 1 Twenty-year survival curve for borderline ovarian tumours
according to histological type. Vaud, Switzerland, 1976–966 F Levi et al
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